Keywords: AstraZeneca, Second-quarter 2011 financial results, Brilinta price
AstraZeneca 2nd-qtr 2011 results in line with forecasts
Article | 28 July 2011
Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning reported second-quarter 2011 financials which beat consensus sales forecasts, with earnings in line ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
